Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab Consolidation in Primary Plasma Cell Leukemia (QUANTUM)
NCT07605416Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2027
- Primary completion
- Nov 2032
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of teclistamab in plasma cell leukemia (PCL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 5 years. Planned start Apr 2027; status: recruiting.
02
Drugs
teclistamab
03
Conditions
plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT07605416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605416.